Wellington Management Group LLP Acquires 638,385 Shares of LifeStance Health Group, Inc. (NASDAQ:LFST)

Wellington Management Group LLP boosted its stake in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 15.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,830,441 shares of the company's stock after buying an additional 638,385 shares during the quarter. Wellington Management Group LLP owned approximately 1.26% of LifeStance Health Group worth $33,813,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. TD Asset Management Inc acquired a new stake in LifeStance Health Group in the 2nd quarter valued at $623,000. Charles Schwab Investment Management Inc. boosted its stake in LifeStance Health Group by 36.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,104,453 shares of the company's stock valued at $7,731,000 after buying an additional 297,723 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in LifeStance Health Group by 24.9% in the third quarter. Point72 Asset Management L.P. now owns 1,100,441 shares of the company's stock worth $7,703,000 after purchasing an additional 219,329 shares in the last quarter. Landscape Capital Management L.L.C. grew its holdings in shares of LifeStance Health Group by 43.7% during the third quarter. Landscape Capital Management L.L.C. now owns 367,935 shares of the company's stock worth $2,576,000 after purchasing an additional 111,894 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of LifeStance Health Group by 6.1% in the third quarter. Principal Financial Group Inc. now owns 4,116,766 shares of the company's stock valued at $28,817,000 after buying an additional 235,316 shares in the last quarter. Institutional investors and hedge funds own 85.50% of the company's stock.

LifeStance Health Group Price Performance

LFST stock traded down $0.06 during trading on Friday, hitting $7.16. The company had a trading volume of 265,798 shares, compared to its average volume of 1,518,235. The firm has a 50-day moving average price of $7.16 and a 200-day moving average price of $6.31. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.32 and a current ratio of 1.32. LifeStance Health Group, Inc. has a 12 month low of $4.64 and a 12 month high of $9.20.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The business had revenue of $312.70 million during the quarter, compared to analysts' expectations of $302.25 million. During the same period in the previous year, the firm earned ($0.17) earnings per share. The firm's quarterly revenue was up 18.9% compared to the same quarter last year. As a group, equities analysts predict that LifeStance Health Group, Inc. will post -0.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LifeStance Health Group news, Director Robert Bessler sold 75,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $7.54, for a total transaction of $565,500.00. Following the sale, the director now directly owns 1,424,447 shares in the company, valued at approximately $10,740,330.38. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 6.60% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. UBS Group decreased their price objective on shares of LifeStance Health Group from $9.00 to $7.50 and set a "neutral" rating on the stock in a report on Thursday, August 15th. Barclays boosted their price objective on shares of LifeStance Health Group from $6.00 to $7.00 and gave the stock an "underweight" rating in a research report on Monday, November 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat.com, LifeStance Health Group has a consensus rating of "Hold" and a consensus price target of $8.50.

LifeStance Health Group Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.